Skip to content
value.today

BlossomHill Therapeutics, Inc.

BLSM
$458 Mmarket cap on Oct 21, 2026
Compare
World rank
#12,964
Revenue
—
annual
Net income
—
Employees
—

BlossomHill Therapeutics, Inc. in brief

BlossomHill Therapeutics, Inc. is a listed company in the Biotechnology industry, based in San Diego, California, USA. Its market value was $458 M on 21 October 2026, which makes it the 12,964th largest listed company in the world and the 2,583rd largest in the USA on this site. Jingrong Jean Cui is its chief executive. Its shares trade under the symbol BLSM (Nasdaq).

Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.

BlossomHill Therapeutics, Inc. timeline

2 events, 2021–2026
  1. 2021
  2. •
    · approximate
    First filing with the US SEC
    The company's first electronic filing in SEC EDGAR.
  3. 2026
  4. 🔔
    Initial public offering on Nasdaq
    Final prospectus filed with the SEC on 7 August 2026; shares registered for exchange trading on 4 August 2026.

Events of BlossomHill Therapeutics, Inc. from SEC EDGAR. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.

Market cap history

$0 M$183 M$366 M$549 M$733 M

World rank over time

▼ down 645 places since 2026
2026-08-01: #12346#12,34620262026-09-29: #11317#11,31720262026-10-21: #12991#12,9912026

Rank in USA: #2,552 (Aug 2026) · #2,329 (Sep 2026) · #2,586 (Oct 2026)

Quarterly results

USD · three months to · source: SEC filings
RevenueNet income
Three months to Jun 2025: revenue —, net income $-13M—Jun ’25Three months to Sep 2025: revenue —, net income $-16M—Sep ’25Three months to Jun 2026: revenue —, net income $-24M—Jun ’26Three months to Sep 2026: revenue —, net income $-24M—Sep ’26

Latest quarter to Sep 2026: revenue —, net income $-24M.

SEC filings

Official filings of BlossomHill Therapeutics, Inc. with the US Securities and Exchange Commission.

Balance sheet

Total assets
$163 M
Total liabilities
$38 M
Total equity
$-132 M

As of December-2025

Top 39 institutional investors in BlossomHill Therapeutics, Inc.#

As of Sep 30, 2026
39 institutions held 16.9 M shares (about 53.2% of the shares outstanding) on Sep 30, 2026. The ten largest hold 48.9%. Source: SEC Form 13F filings, filed through Nov 16, 2026. Change is since the previous quarter.This quarter is still being filed: about 99% of the institutions that reported last quarter have filed so far. Institutions that have not filed yet are missing from the list, not sellers; the list is brought up to date every day.
The 25 largest institutional investors in BlossomHill Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
1Cormorant Asset Management, LP3,614,034New11.37%$67 MNov 16, 2026
2Orbimed Advisors LLC2,714,279New8.54%$51 MNov 16, 2026
3Perceptive Advisors LLC1,812,193New5.70%$34 MNov 16, 2026
4Vivo Capital, LLC1,493,740New4.70%$28 MNov 13, 2026
5Deerfield Management Company, L.P.1,446,000New4.55%$27 MNov 16, 2026
6Jpmorgan Chase & Co1,415,331New4.45%$26 MNov 12, 2026
7Janus Henderson Group Ltd.1,336,993—4.21%$25 MNov 16, 2026
8FMR LLC1,027,293New3.23%$19 MNov 10, 2026
9Vanguard Capital Management LLC433,302New1.36%$8 MNov 13, 2026
10NEXTBio Capital Management LP250,000New0.79%$5 MNov 13, 2026
11Silverarc Capital Management, LLC202,104New0.64%$4 MNov 12, 2026
12Opaleye Management Inc.175,000New0.55%$3 MNov 16, 2026
13BlackRock, Inc.147,686New0.46%$3 MNov 13, 2026
14a16z Capital Management, L.L.C.125,000New0.39%$2 MNov 16, 2026
15Geode Capital Management, LLC119,176New0.37%$2 MNov 6, 2026
16Monashee Investment Management LLC80,000New0.25%$1 MNov 6, 2026
17Ameriprise Financial Inc73,691New0.23%$1 MNov 16, 2026
18Vanguard Fiduciary Trust Co60,281New0.19%$1 MNov 13, 2026
19Citadel Advisors LLC55,000New0.17%$1 MNov 16, 2026
20Birchview Capital, LP50,000New0.16%$1 MNov 13, 2026
21Ghisallo Capital Management LLC50,000New0.16%$1 MNov 16, 2026
22Millennium Management LLC45,818New0.14%$1 MNov 16, 2026
23Goldman Sachs Group Inc30,805New0.10%$1 MNov 16, 2026
24Walleye Capital LLC28,659New0.09%$1 MNov 13, 2026
25Squarepoint Ops LLC23,150New0.07%$0 MNov 9, 2026
Show all 39: investors 26 to 39
Institutional investors 26 to 39 in BlossomHill Therapeutics, Inc.
#InstitutionShares heldChange (shares)% heldValueFiled
26Northern Trust Corp21,337New0.07%$0 MNov 16, 2026
27State Street Corp17,200New0.05%$0 MNov 12, 2026
28D. E. Shaw & Co., Inc.12,034New0.04%$0 MNov 16, 2026
29Vanguard Portfolio Management LLC10,932New0.03%$0 MNov 13, 2026
30Jump Financial, LLC10,223New0.03%$0 MNov 13, 2026
31Charles Schwab Investment Management Inc10,194New0.03%$0 MNov 16, 2026
32Two Sigma Investments, LP10,100New0.03%$0 MNov 16, 2026
33Aster Capital Management (DIFC) Ltd4,822New0.02%$0 MNov 12, 2026
34Morgan Stanley4,677New0.01%$0 MNov 13, 2026
35Vanguard Global Advisers, LLC3,765New0.01%$0 MNov 13, 2026
36Legal & General Group Plc1,612New0.01%$0 MNov 16, 2026
37Citigroup Inc1,279New0.00%$0 MNov 4, 2026
38UBS Group AG997New0.00%$0 MNov 10, 2026
39Osaic Holdings, Inc.512New0.00%$0 MNov 12, 2026

Insider trading at BlossomHill Therapeutics, Inc.#

Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.

Bought, 12 months
$15.2 M
7 purchases, 6 insiders
Sold, 12 months
$0
0 sales, 0 insiders
Net, 12 months
$15.2 M
open market only
Insiders on file
9
since
BlossomHill Therapeutics, Inc.: latest insider trades
TradedInsiderTradeSharesPriceValueOwned afterFiling
filed OrbiMed Capital GP VIII LLCDirectorConversionindirect+1.04 M——1.04 MForm 4
filed Carl L. GordonDirectorConversionindirect+1.04 M——1.04 MForm 4
filed OrbiMed Capital GP VIII LLCDirectorConversionindirect+1.05 M——2.09 MForm 4
filed Carl L. GordonDirectorConversionindirect+1.05 M——2.09 MForm 4
filed OrbiMed Capital GP VIII LLCDirectorBuyindirect+625,000$16.00$10.0 M2.71 MForm 4
filed Carl L. GordonDirectorBuyindirect+625,000$16.00—2.71 MForm 4
filed Yishan LiExecutive Chairman, Director, 10% ownerConversionindirect+1.60 M——1.60 MForm 4
filed Jason A. KeyesChief Financial OfficerBuy+700$16.00$11 K700Form 4

Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals

Markets and events: BlossomHill Therapeutics, Inc.#

Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.

Short interest, 2026-10-30
590,133
4.65 days to cover
Shares sold short, last 6 reportsAll stocks →

IPO: priced at $16.00, raising $150M · IPO calendar

Fails to deliver

  • : 2,204 shares at $14.40
  • : 1,026 shares at $21.34
  • : 3,794 shares at $20.47
  • : 4,322 shares at $22.34
  • : 20,078 shares at $25.25

Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables

BlossomHill Therapeutics, Inc. scorecard#

Passes 1 of the 2 checks that could be worked out. Fiscal year 2025; market cap of Oct 21, 2026.

  • Valuation0 of 1
    • –P/E below its peers' medianNo P/E on file.
    • ✗Price to book below its peers' medianNo price to bookShareholders' equity is negative.
    • –Price to sales below its peers' medianNo Price to sales on file.
    • –Free cash flow yield above 5%No free cash flow yield on file.
    • –Earnings yield above the 10-year Treasury yieldNo P/E on file.
    • –The price assumes slower growth than the last three years'Free cash flow of the last three years is missing or below zero on average.
  • Growthnot known
    • –Revenue grew in the newest yearRevenue of the year before is not on file.
    • –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
    • –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
    • –Earnings per share grew in the newest yearEarnings per share of two years are not on file.
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitabilitynot known
    • –Profitable in the newest yearNo net income on file.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • –Operating margin above its peers' medianNo operating margin on file.
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
  • Financial health1 of 1
    • ✓Short-term assets cover short-term liabilities9.0×Current ratio 8.97 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • –Net debt below three years of EBITDANet debt to EBITDA is not on file.
    • –Operating income covers interest five timesInterest expense is not on file.
    • –Cash from operations positive in each of the last three yearsThree years of operating cash flow are not on file.
    • –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
  • Shareholder returnsnot known
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • –Share count up no more than 2% in a yearShare counts of two years are not on file.
    • –Dividends and buybacks above 3% of the market valueDividends and buybacks are not on file.
    • –Free cash flow covers dividends and buybacksCash from operations or capital spending is not on file.

Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap. A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

Events at BlossomHill Therapeutics, Inc.#

What the company reported to the SEC within four business days (Form 8-K), newest first.

No warning signs in the last three years: no bankruptcy, delisting notice, withdrawn financial statements, auditor change, cybersecurity incident, debt called early or impairment was reported.

Bylaws or fiscal year changed 1 · Results announced 2

BlossomHill Therapeutics, Inc.: events reported to the SEC
FiledWhat happenedFiling
Results announced8-K
Results announced8-K
Bylaws or fiscal year changed8-K

Source: SEC EDGAR, Form 8-K item numbers · as of Nov 12, 2026

Acquisitions and funding#

4 private funding rounds before listing

Private share sales · funding history

Private share sales of BlossomHill Therapeutics, Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Nov 2025$84 MNo. 4$50 to $250 million47equitySEC
Dec 2023$89 MNo. 3$50 to $250 million44equitySEC
Mar 2021$71 MNo. 2$50 to $250 million27equitySEC
Dec 2020$2 MNo. 1$2 to $10 million3equitySEC

Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.

H-1B hiring at BlossomHill Therapeutics, Inc.#

1 labor condition applications certified in fiscal 2026 for 1 positions, at a median wage of $101 K a year.

Certified, FY2026
1
#1,949 among companies on value.today
Worker positions
1
Median wage offered
$101 K
a year, full-time
Applications filed
1
BlossomHill Therapeutics, Inc.: most frequent H-1B job titles in fiscal 2026
Job titlePositionsMedian wage offered
Programming Analyst 2, Clinical TrialsComputer Systems Analysts1$101 K

Where: San Diego, CA 1

BlossomHill Therapeutics, Inc.: labor condition applications by fiscal year
Fiscal yearCertifiedPositionsMedian wageFiled
FY202611$101 K1
FY202511$432 K1

Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as BlossomHill Therapeutics, Inc.

Discuss BlossomHill Therapeutics, Inc.#

1 automatic updates and 0 member comments. Sign in to comment and react.

  • Results announced on 12 November 2026automatic update · Nov 12, 2026

    BlossomHill Therapeutics, Inc. announced results on 12 November 2026 (SEC Form 8-K, item 2.02). For the quarter ended 30 September 2026: a net loss of $24 million.

How BlossomHill Therapeutics, Inc. compares in Biotechnology

Peer comparison · Biotechnology

CompanyMarket capP/ENet marginRev. growth
BlossomHill Therapeutics, Inc.🇺🇸$458 M———
Novo Nordisk A/S🇩🇰$203.2 B13.1×33.1%+10.8%
Vertex Pharmaceuticals Incorporated🇺🇸$134.3 B33.8×30.7%+8.9%
Moderna, Inc.🇺🇸$90.1 B—-110.5%-39.9%
Regeneron Pharmaceuticals, Inc.🇺🇸$84.1 B17.5×28.5%+1.0%
Argenx SE🇳🇱$52.8 B40.9×31.1%+89.9%
CSL Limited🇦🇺$51.6 B—-16.4%—
Samsung Biologics Co., Ltd.🇰🇷$51.5 B40.5×39.2%—
UCB SA🇧🇪$48.6 B26.3×20.1%+31.1%

P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.

Questions, comparisons and similar companies#

Sources and freshness

Market cap:
Oct 21, 2026
Balance sheet:
As of December-2025
Profile updated:
Nov 20, 2026

Figures from Market data, SEC filing, value.today research; financial statements from SEC filings.

How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.

Work at BlossomHill Therapeutics, Inc.? Verify and update this profile — free

Use your work e-mail address (on the company's own domain if possible). Fill in only what is new or missing; a link to where the figures are published (annual report, press release) speeds up the review.

Show BlossomHill Therapeutics, Inc.'s ranking on your website Get the badge
Badge preview

The badge updates itself as the ranking changes.

Something wrong or missing about BlossomHill Therapeutics, Inc.? Suggest a correction